Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis

Osteoarthritis and Cartilage

Volumn 19, Issue 7, 2011, Pages 874-885

  Chan, B Y ^a   Fuller, E S ^a   Russell, A K ^a   Smith, S M ^a   Smith, M M ^a   Jackson, M T ^a   Cake, M A ^b   Read, R A ^b   Bateman, J F ^c   Sambrook, P N ^a   Little, C B ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MURDOCH UNIVERSITY   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

catenin; ADAMTS; Cartilage; MMPs; Osteoarthritis; Sclerostin

Indexed keywords

ADAMTS1 PROTEIN; AGGRECAN; BETA CATENIN; COLLAGEN TYPE 2; INTERLEUKIN 1ALPHA; MATRIX METALLOPROTEINASE; MESSENGER RNA; SCLEROSTIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CARTILAGE MATRIX; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPLANT; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; IN VITRO STUDY; KNEE; KNEE ARTHROPLASTY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOARTHRITIS; OSTEOSCLEROSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SHEEP; UPREGULATION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CARTILAGE, ARTICULAR; CHONDROCYTES; HUMANS; INTERLEUKIN-1ALPHA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; OSTEOARTHRITIS, KNEE; RNA, MESSENGER; SHEEP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959936613     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2011.04.014     Document Type: Article

References (51)

1. Roos H., Adalberth T., Dahlberg L., Lohmander L.S. Osteoarthritis of the knee after injury to the anterior cruciate ligament or meniscus: the influence of time and age. Osteoarthritis Cartilage 1995, 3:261-267.
2. Jacobsen K. Osteoarthrosis following insufficiency of the cruciate ligaments in man. A clinical study. Acta Orthop Scand 1977, 48:520-526.
3. Felson D.T. Developments in the clinical understanding of osteoarthritis. Arthritis Res Ther 2009, 11:203.
4. Karsdal M.A., Leeming D.J., Dam E.B., Henriksen K., Alexandersen P., Pastoureau P., et al. Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthritis Cartilage 2008, 16:638-646.
5. Beyer C., Schett G. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel targets in bone and cartilage. Best Pract Res Clin Rheumatol 2010, 24:489-496.
6. Blom A.B., van Lent P.L., van der Kraan P.M., van den Berg W.B. To seek shelter from the WNT in osteoarthritis? WNT-signaling as a target for osteoarthritis therapy. Curr Drug Targets 2010, 11:620-629.
7. Hoeppner L.H., Secreto F.J., Westendorf J.J. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 2009, 13:485-496.
8. Kawaguchi H. Regulation of osteoarthritis development by Wnt-beta-catenin signaling through the endochondral ossification process. J Bone Miner Res 2009, 24:8-11.
9. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., Dwyer D., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163.
10. Yuasa T., Otani T., Koike T., Iwamoto M., Enomoto-Iwamoto M. Wnt/beta-catenin signaling stimulates matrix catabolic genes and activity in articular chondrocytes: its possible role in joint degeneration. Lab Invest 2008, 88:264-274.
11. Blom A.B., Brockbank S.M., van Lent P.L., van Beuningen H.M., Geurts J., Takahashi N., et al. Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt-induced signaling protein 1. Arthritis Rheum 2009, 60:501-512.
12. Zhu M., Tang D., Wu Q., Hao S., Chen M., Xie C., et al. Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Miner Res 2009, 23:10.
13. Voorzanger-Rousselot N., Ben-Tabassi N.C., Garnero P. Opposite relationships between circulating Dkk-1 and cartilage breakdown in patients with rheumatoid arthritis and knee osteoarthritis. Ann Rheum Dis 2009, 68:1513-1514.
14. Lories R.J., Peeters J., Bakker A., Tylzanowski P., Derese I., Schrooten J., et al. Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice. Arthritis Rheum 2007, 56:4095-4103.
15. Zhu M., Chen M., Zuscik M., Wu Q., Wang Y.J., Rosier R.N., et al. Inhibition of beta-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthritis Rheum 2008, 58:2053-2064.
16. Weng L.H., Wang C.J., Ko J.Y., Sun Y.C., Su Y.S., Wang F.S. Inflammation induction of Dickkopf-1 mediates chondrocyte apoptosis in osteoarthritic joint. Osteoarthritis Cartilage 2009, 17:919-929.
17. Weng L.H., Wang C.J., Ko J.Y., Sun Y.C., Wang F.S. Control of Dickkopf-1 ameliorates chondrocyte apoptosis, cartilage destruction and subchondral bone deterioration in osteoarthritic knee. Arthritis Rheum 2010, 62:1393-1402.
18. Krause C., Korchynskyi O., de Rooij K.E., Weidauer S.E., de Gorter D.J., van Bezooijen R.L., et al. Distinct modes of inhibition by Sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 2010, 285:41614-41626.
19. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005, 280:26770-26775.
20. van Bezooijen R.L., Roelen B.A., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004, 199:805-814.
21. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008, 23:860-869.
22. Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I., et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008, 283:5866-5875.
23. Heiland G.R., Zwerina K., Baum W., Kireva T., Distler J.H., Grisanti M., et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010, 69:2152-2159.
24. Vincent C., Findlay D.M., Welldon K.J., Wijenayaka A.R., Zheng T.S., Haynes D.R., et al. The Proinflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009, 17:17.
25. Power J., Poole K.E., van Bezooijen R., Doube M., Caballero-Alias A.M., Lowik C., et al. Sclerostin and the regulation of bone formation: effects in hip osteoarthritis and femoral neck fracture. J Bone Miner Res 2010, 25:1867-1876.
26. Appel H., Ruiz-Heiland G., Listing J., Zwerina J., Herrmann M., Mueller R., et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009, 60:3257-3262.
27. van Bezooijen R.L., Bronckers A.L., Gortzak R.A., Hogendoorn P.C., van der Wee-Pals L., Balemans W., et al. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res 2009, 88:569-574.
28. Karlsson C., Dehne T., Lindahl A., Brittberg M., Pruss A., Sittinger M., et al. Genome-wide expression profiling reveals new candidate genes associated with osteoarthritis. Osteoarthritis Cartilage 2010, 18:581-592.
29. Armstrong S., Read R., Ghosh P. The effects of intraarticular hyaluronan on cartilage and subchondral bone changes in an ovine model of early osteoarthritis. J Rheumatol 1994, 21:680-688.
30. Little C.B., Smith M.M., Cake M.A., Read R.A., Murphy M.J., Barry F.P. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in sheep and goats. Osteoarthritis Cartilage 2010, 18(Suppl 3):S80-S92.
31. Little C., Meeker C., Golub S., Lawlor K., Farmer P., Smith S., et al. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promoters cartilage repair. J Clin Invest 2007, 117:1627.
32. Glasson S.S., Blanchet T.J., Morris E.A. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage 2007, 15:1061-1069.
33. Little C.B., Barai A., Burkhardt D., Smith S.M., Fosang A.J., Werb Z., et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009, 60:3723-3733.
34. Young A.A., Appleyard R.C., Smith M.M., Melrose J., Little C.B. Dynamic biomechanics correlate with histopathology in human tibial cartilage: a preliminary study. Clin Orthop Relat Res 2007, 462:212-220.
35. Little C., Smith S., Ghosh P., Bellenger C. Histomorphological and immunohistochemical evaluation of joint changes in a model of osteoarthritis induced by lateral meniscectomy in sheep. J Rheumatol 1997, 24:2199-2209.
36. Jackson M.T., Smith M.M., Smith S.M., Jackson C.J., Xue M., Little C.B. Activation of cartilage matrix metalloproteinases by activated protein C. Arthritis Rheum 2009, 60:780-791.
37. Smith M.M., Sakurai G., Smith S.M., Young A.A., Melrose J., Stewart C.M., et al. Modulation of aggrecan and ADAMTS expression in ovine tendinopathy induced by altered strain. Arthritis Rheum 2008, 58:1055-1066.
38. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000, 25:169-193.
39. Bustin S.A. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002, 29:23-39.
40. Dell'accio F., De Bari C., Eltawil N.M., Vanhummelen P., Pitzalis C. Identification of the molecular response of articular cartilage to injury, by microarray screening: Wnt-16 expression and signaling after injury and in osteoarthritis. Arthritis Rheum 2008, 58:1410-1421.
41. Liu X.H., Kirschenbaum A., Weinstein B.M., Zaidi M., Yao S., Levine A.C. Prostaglandin E2 modulates components of the Wnt signaling system in bone and prostate cancer cells. Biochem Biophys Res Commun 2010, 394:715-720.
42. Corr M. Wnt-beta-catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol 2008, 4:550-556.
43. Choi H.Y., Dieckmann M., Herz J., Niemeier A. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE 2009, 4. e7930.
44. Aigner T., Soeder S., Haag J. IL-1beta and BMPs-interactive players of cartilage matrix degradation and regeneration. Eur Cell Mater 2006, 12:49-56. discussion 56.
45. Grotewold L., Ruther U. The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J 2002, 21:966-975.
46. Loots G.G., Kneissel M., Keller H., Baptist M., Chang J., Collette N.M., et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005, 15:928-935.
47. Ryu J.H., Chun J.S. Opposing roles of WNT-5A and WNT-11 in interleukin-1beta regulation of type II collagen expression in articular chondrocytes. J Biol Chem 2006, 281:22039-22047.
48. Kobayashi M., Squires G.R., Mousa A., Tanzer M., Zukor D.J., Antoniou J., et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 2005, 52:128-135.
49. Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J., et al. Sclerostin mediates bone response to mechanical unloading via antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009, 24:1651-1661.
50. Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24:578-588.
51. Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 2009, 5:20-27.